• 主题
高级搜索  >
历史搜索 清空历史
首页> 美国卫生研究院文献>Journal of Experimental Clinical Cancer Research : CR >The changing face of clinical trials in the personalized medicine and immuno-oncology era: report from the international congress on clinical trials in Oncology Hemato-Oncology (ICTO 2017)
【2h】

The changing face of clinical trials in the personalized medicine and immuno-oncology era: report from the international congress on clinical trials in Oncology Hemato-Oncology (ICTO 2017)

机译：个性化医学和免疫肿瘤学时代临床试验的变化面孔：国际肿瘤学和血液肿瘤学国际临床试验大会的报告（ICTO 2017）

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

In the past decade, the oncology community has witnessed major advances in the understanding of cancer biology and major breakthroughs in several different therapeutic areas, from solid tumors to hematological malignancies; moreover, the advent of effective immunotherapy approaches, such as immune-checkpoint blockade, is revolutionizing treatment algorithms in almost all oncology disease areas. As knowledge evolves and new weapons emerge in the “war against cancer”, clinical and translational research need to adapt to a rapidly changing environment to effectively translate novel concepts into sustainable and accessible therapeutic options for cancer patients.With this in mind, translational cancer researchers, oncology professionals, treatment experts, CRO and industry leaders, as well as patient representatives gathered in London, 16-17 March 2017, for The International Congress on Clinical Trials in Oncology and Hemato-Oncology (ICTO2017), to discuss the changing face of oncology clinical trials in the new era of personalized medicine and immuno-oncology. A wide range of topics, including clinical trial design in immuno-oncology, biomarker-oriented drug development paths, statistical design and endpoint selection, challenges in the design and conduct of personalized medicine clinical trials, risk-based monitoring, financing and reimbursement, as well as best operational practices, were discussed in an open, highly interactive format, favoring networking among all relevant stakeholders. The most relevant data, approaches and issues emerged and discussed during the conference are summarized in this report.
机译：在过去的十年中，肿瘤学界在癌症生物学认识上取得了重大进展，并在从实体瘤到血液系统恶性肿瘤的几个不同治疗领域取得了重大突破。此外，有效的免疫治疗方法（如免疫检查点封锁）的出现正在彻底改变几乎所有肿瘤疾病领域的治疗算法。随着知识的发展和“抗癌战争”中新武器的出现，临床和转化研究需要适应迅速变化的环境，以有效地将新概念转化为癌症患者的可持续和可及的治疗选择。 ，肿瘤学专业人士，治疗专家，CRO和行业领导者以及患者代表于2017年3月16日至17日聚集在伦敦，参加了国际肿瘤学和血液肿瘤临床试验大会（ICTO2017），以讨论肿瘤的不断变化的面貌。个性化医学和免疫肿瘤学新时代的肿瘤学临床试验。广泛的主题，包括免疫肿瘤学的临床试验设计，面向生物标志物的药物开发途径，统计设计和终点选择，个性化药物临床试验的设计和进行中的挑战，基于风险的监测，融资和报销，以开放，高度互动的形式讨论了最佳操作实践，并促进了所有相关利益相关方之间的联网。报告总结了会议期间出现和讨论的最相关的数据，方法和问题。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号